SHPAX Mutual Fund

SHPAX Mutual Fund

NAV$25.68
See how much of SHPAX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Aug 31, 2026

Net Assets
$5M
Expense Ratio
3.00%
Dividend Yield (Current)
-
Holdings
29
Inception Date
Jul 15, 1999
Fund Family
Saratoga Capital Management, LLC
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+16.76%
1 Year+25.17%
3 Year+14.70%
5 Year+7.44%
10 Year+8.45%

Asset Allocation

Stocks: 98.39%
Cash: 1.61%
See how much of SHPAX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report comes with FundXLS. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
JAZZJazz Pharmaceuticals Plc.5.92%
AMGNAmgen Inc.5.81%
MCKMckesson Corp.5.27%
CAHCardinal Health5.11%
UTHRUnited Therapeutics Corp5.10%
Top 10 Concentration: 49.25%Report Date: Aug 31, 2026
Download all 29 holdings for SHPAX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Annually
Latest Distribution
$0.79
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

SHPAX Mutual Fund Overview

SHPAX Mutual Fund (Saratoga Health & Biotechnology Portfolio Class A) is managed by Saratoga Capital Management, LLC with $5.4M in net assets. SHPAX expense ratio is 3.00%, holding 29 positions across sectors including Health Care, Financials. Inception date: 1999-07-15.

SHPAX performance shows a YTD return of 16.76%. The 1-year return is 25.17% and the 5-year return is 7.44%.

SHPAX top holdings include Jazz Pharmaceuticals Plc. (5.9%), Amgen Inc. (5.8%), Mckesson Corp. (5.3%), Cardinal Health (5.1%), United Therapeutics Corp (5.1%). Go to all SHPAX holdings, SHPAX sectors, or SHPAX dividends.

SHPAX can be compared against other funds. Use SHPAX overlap to find shared positions, or SHPAX vs another fund for a side-by-side view. SHPAX alternatives are available via the screener, along with tax-loss harvesting opportunities.